BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Six-Year Study Confirms Australia's Sirtex Medical's Liver Cancer Therapy is Safe and Effective


7/7/2011 8:06:32 AM

7 July 2011 -- Oncology treatment company Sirtex Medical (ASX: SRX) today announced the publication of a six-year retrospective analysis of 325 patients treated with its targeted radioactive SIR-Spheres® microspheres therapy for inoperable primary liver cancer.

The study is the largest multi-centre evaluation of radioembolisation (also known as Selective Internal Radiation Therapy or SIRT) using SIR-Spheres® microspheres for patients with inoperable primary liver cancer and the results confirm that the treatment was safe and effective in a range of patients with early to advanced stages of the disease. Independent researchers at eight European treatment centres reported “robust evidence of the survival achieved” using SIR-Spheres® microspheres, “including patients with advanced disease and few treatment options.”

Sirtex Chief Executive Officer, Mr Gilman Wong, said, “These positive results build on the growing body of robust clinical evidence that demonstrates SIR-Spheres® microspheres deliver very encouraging clinical outcomes across the different stages of liver cancer.”

“This new data will further support the expanding use of SIR-Spheres® microspheres in a wider patient population and bolster our efforts to support medical professionals treating liver cancer patients at over 400 treatment centres worldwide,” Mr Wong said.

The full results of the multi-centre retrospective analysis called ENRY (European Network on Radioembolisation with Yttrium-90 Resin Microspheres) are published in the peer-reviewed journal of the American Association of the Study of Liver Diseases, Hepatology.

A summary of the key findings is attached and a full reprint is available online at

http://onlinelibrary.wiley.com/doi/10.1002/hep.24451/full or by contacting Sirtex.

Andrew Geddes

City Public Relations

Level 6, 155 George Street

The Rocks Sydney NSW 2000

Direct: (02) 8916 4845

Switch: (02) 8916 4848

Mobile: 0408 677 734



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES